Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
0Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
MAIA Biotechnology, Inc. (MAIA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
6Distinct source URLs
8High confidence
0.872Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
MAIA Biotechnology, Inc. Suppliers
Ticker
Name
Confidence
Evidence
H-C-WAINWRIGHT-CO-LLC
H-C-WAINWRIGHT-CO-LLC
92%
the Company's sales agent thereunder
KONIK-CAPITAL-PARTNERS-LLC
KONIK-CAPITAL-PARTNERS-LLC
92%
the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“…
In February 2021, the Company entered into a Drug Supply Agreement (the “Drug Supply Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”) to perform one clinical trial for the treatment of …
Reciprocal relationship from REGN graph: Reciprocal relationship from MAIA graph: In February 2021, the Company entered into a Drug Supply Agreement (the “Drug Supply Agreement”) with Regeneron Pharm…
UTSW
UTSW
90%
Pursuant to the UTSW1 Agreement, the Company paid to UTSW a nominal one-time upfront license fee.
ncy. In addition to its own review, the FDA may refer applications for novel drug or biological products or drug or biological products which present difficult questions of safety or efficacy to an a…
Reciprocal relationship from ORANY graph: Reciprocal relationship from MAIA graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from MAIA graph: ncy. In addition to its own revie…
MAIA Biotechnology, Inc. Customers
No clients on recordMAIA Biotechnology, Inc. does not appear to disclose named customer relationships in its verified regulatory filings. Many companies do not publicly name customers in regulatory disclosures.
MAIA Biotechnology, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MAIA-DEBT-10859
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
MAIA-DEBT-10858
Warrants outstanding: 452731
90%
xbrl warrant detail from xbrl 2025-12-31.
MAIA Biotechnology, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for MAIA Biotechnology, Inc..
MAIA Biotechnology, Inc. Ownership
Holder
Name
Confidence
Evidence
MAIA-OWNER-SOLAS-CAPITAL-MANAGEMENT-LLC
Solas Capital Management, LLC
90%
13F overlay lists Solas Capital Management, LLC as top holder; 32 tracked holders.
MAIA Biotechnology, Inc. Extended Supply Chain Network
